Program:
Start Year:
2023
Why did you choose Duke for your fellowship training?
I chose Duke for gynecologic oncology fellowship because Duke's program offers exceptional surgical, clinical and research experiences in addition to a supportive work environment. I was fortunate to have received training as a resident at Duke and was able see first-hand the mentorship that the attendings and fellows in the division provide. Lastly, my husband and I love living in Durham and all that it has to offer!
What excites you about the fellowship program at Duke Obstetrics & Gynecology?
I am really excited to receive comprehensive training that will prepare me well for a successful career as an academic gynecologic oncologist. In addition, I am excited to work with the residents and medical students who rotate on our service.
What are your career goals?
I hope to be an academic gynecologic oncologist and remain active with research and the education of trainees.
What are your hobbies?
hiking, running, traveling to the beach or mountains with my husband
Education & Training
Undergraduate school & graduation year:
Samford University, 2015
Medical school & graduation year:
University of South Carolina School of Medicine Greenville, 2019
Residency & graduation year:
Duke University, 2023
Awards and Honors
Duke Golden Apple Award (2022)
Duke OB/GYN Appleseed Resident Teaching Award (2021, 2022)
Society of Gynecologic Oncology Outstanding Resident in Gynecologic Oncology (2022)
Duke OB/GYN Excellence in Physician Assistant Student Teaching Award (2021)
Alpha Omega Alpha Honor Medical Society, University of South Carolina School of Medicine Greenville (2018)
Christopher Michael McManus Memorial Scholarship, University of South Carolina School of Medicine Greenville (2018)
Alpha Epsilon Delta Health Professional Honor Society, Samford University (2014)
Wilcox Scholarship, Samford University (2013)
Wheeler, Seal, and Tower Biology Awards, Samford University (2012-2014)
Presidential Scholarship, Samford University (2011-2014)
Gamma Sigma Alpha Greek Honor Society, Samford University (2012-2013)
Alpha Lambda Delta Honor Society, Samford University (2011-2012)
Publications
Anastasio MK, Anastasio AT, Kuller JA. Peripartum Pubic Symphysis Diastasis. Obstet Gynecol Surv. 2023 Jun;78(6):369-375. doi: 10.1097/OGX.0000000000001156. PMID: 37322998.
Anastasio MK, Gupta A, Akinyemiju TF, Previs RA. Healthcare access dimensions and uterine cancer survival: a national cancer database study. Front Oncol. 2023 Oct 5;13:1263371. doi: 10.3389/fonc.2023.1263371. PMID: 37869101; PMCID: PMC10585829.
Anastasio MK, Unnithan S, Scott A, Hayes T, Shah S, Moss HA, Erkanli A, Havrilesky LJ. Cryocompression to Reduce Peripheral Neuropathy in Gynecologic Cancer: A Randomized Controlled Trial. Obstet Gynecol. 2023 Oct 26. doi: 10.1097/AOG.0000000000005419. Epub ahead of print. PMID: 37883997.
Montes de Oca MK, Wilson LE., Previs RA, Gupta A, Joshi A, Huang B, Pisu M, Liang M, Ward KC, Schymura MJ, Berchuck A, & Akinyemiju TF. Healthcare Access Dimensions and Guideline-Concordant Ovarian Cancer Treatment: SEER-Medicare Analysis of the ORCHiD Study, Journal of the National Comprehensive Cancer Network. 2022; 20(11), 1255-1266.e11. PMID 36351338
Montes de Oca MK, Chen Q, Howell E, Wilson LE, Meernik C, Previs RA, Huang B, Pisu M, Liang M, Ward KC, Schymura MJ, Berchuck A, Akinyemiju T. Healthcare Access Dimensions and Ovarian Cancer Survival: SEER-Medicare Analysis of the ORCHiD Study, Accepted in Journal of the National Cancer Institute Cancer Spectrum 2023
Montes de Oca MK, Howell EP, Spinosa D, Knochenhauer H, Peipert BJ, Severson E, Ramkissoon S, Akinyemiju TF, Previs RA. Diversity and transparency in gynecologic oncology clinical trials. Cancer Causes Control. 2022 Oct 25. doi: 10.1007/s10552-022-01646-y. Epub ahead of print. PMID: 36284031.
Reid H, Selvan B, Montes de Oca MK, Falkovic M, Malone S, Fish LJ, Wheeler S, Davidson BA. “You start feeling comfortable, you just start sharing:” A qualitative study of patient distress screening in Black and White patients with endometrial cancer. Gynecologic Oncology. 2023; 168, 166-175, doi.org/10.1016/j.ygyno.2022.11.008. PMID: 36502783
Reid HW, Broadwater G, Montes de Oca MK, Selvan B, Fayanju O, Havrilesky LJ, Davidson BA. Distress screening in endometrial cancer leads to disparity in referral to support services. Gynecol Oncol. 2022 Jan 8:S0090-8258(22)00001-4. doi: 10.1016/j.ygyno.2022.01.001. PMID 35016785
Montes de Oca MK, Albright BB, Secord AA, Havrilesky LJ, Moss HA. Adjuvant treatment and outcomes for patients with stage IIIA grade 1 endometrioid endometrial cancer. International Journal of Gynecologic Cancer. 2021. doi: 10.1136/ijgc-2021-002884. PMID 34725205.
Montes de Oca MK, Dotters-Katz S, Kuller JA, Previs RA. Adnexal masses in pregnancy. Obstet Gynecol Surv. 2021 Jul;76(7):437-450. PMID 34324696.
Monuszko KA, Albright B, Montes De Oca MK, Nguyen T, Havrilesky LJ, Davidson BA. Evaluation of the clinical index of stable febrile neutropenia risk stratification system for management of febrile neutropenia in gynecologic oncology patients. Gynecol Oncol Rep. 2021 Aug 27;37:100853. doi: 10.1016/j.gore.2021.100853. PMID: 34504931; PMCID: PMC8414105.
Watson C, Broadwater G, Wong J, Spinosa D, Montes de Oca MK, Datto M, Green M, Hubbard C, McKinney M, McCall S, Havrilesky L, Strickler J, Berchuck A, Strickland K, Previs R. Results and clinical utilization of foundation medicine molecular tumor profiling in uterine and ovarian cancers. Targeted Oncology 2021; 16: 109-118. PMID 33400095.
Montes de Oca MK, Nye A, Porter C, Collins J, Satterfield C, Schammel CMG, Trocha SD. Head and neck cancer PEG site metastases—Case Report, Meta-analysis and Literature Review. Head & Neck. 2019;1-9. PMID 30614611.
Nye A, Collins JD, Porter CL, Montes de Oca MK, George K, Stafford CG, Schammel C, Horton S, Trocha SD. Predictive Genetic Profiles for Regional Lymph Node Metastasis in Primary Cutaneous Melanoma: A Case Matched Pilot Study. 2018. Melanoma Research. 2018; 28(6):555-561. PMID 30179987.
Sharma P, Montes de Oca MK, Alkeswani AR, et al. Tea polyphenols for the prevention of UVB-induced skin cancer. Photodermatol Photoimmunol Photomed 2018; 34:50-59. PMID 29044724.
Montes de Oca MK, Jamison RA. Pancreatic panniculitis as the initial presentation of intrahepatic cholangiocarcinoma. Journal of the American Academy of Dermatology Case Reports 2018; 4(6):528-530. PMID 30023419.
Montes de Oca MK, Pearlman RL, McClees SF, Strickland R, Afaq F. Phytochemicals for the prevention of photocarcinogenesis. Photochem Photobiol 2017; 93(4):956-974.
Pearlman RL, Montes de Oca MK, Pal HC and Afaq F. Potential therapeutic targets of epithelial‐mesenchymal transition in melanoma. Cancer Lett 2017; 391:125-140.
Le T, Bhushan V, Sochat M, Montes de Oca, MK, et al. [Contributing Author] In: First Aid for the USMLE Step 1, 30th ed. New York: McGraw-Hill, 2020.
Spinosa D, Montes de Oca MK, Watson C, Berchuck A, Previs R. Endometrial cancer. Genomic and precision medicine: Volume 5, Oncology.
Presentations
Anastasio, MK; Unnithan, S; Scott, A; Hayes, T; Shah, S; Moss, H; Erklani, A; Havrilesky, LJ. Cryocompression to reduce peripheral neuropathy in gynecologic cancer: a randomized controlled trial. Society of Gynecologic Oncology 2023 Virtual Annual Meeting on Women’s Cancer, March 25, 2023.
Montes de Oca, MK; Wu, K; Strickland, K; Previs, R. Exploring associations between tumor mutational burden and survival in uterine cancers. Mid-Atlantic Gynecologic Oncology Society 2021 Annual Meeting, October 22, 2021.
Montes de Oca, MK; Albright, B; Havrilesky, L; Moss, H. The subjective interpretation of negative trial results during oral plenary presentations. Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer, March 21, 2021.
Montes de Oca, MK; Albright, B; Havrilesky, L; Moss, H. The subjective interpretation of negative trial results during oral plenary presentations. Mid-Atlantic Gynecologic Oncology Society 2020 Annual Meeting, October 24, 2020.
Research Interests
My research interests include clinical trials, health equity, and improving quality of life for patients with gynecologic cancer